JP2025503096A - がんの処置および撮像のための複合体 - Google Patents

がんの処置および撮像のための複合体 Download PDF

Info

Publication number
JP2025503096A
JP2025503096A JP2024543372A JP2024543372A JP2025503096A JP 2025503096 A JP2025503096 A JP 2025503096A JP 2024543372 A JP2024543372 A JP 2024543372A JP 2024543372 A JP2024543372 A JP 2024543372A JP 2025503096 A JP2025503096 A JP 2025503096A
Authority
JP
Japan
Prior art keywords
radionuclide
present
pharmaceutical composition
complex
malignant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024543372A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025503096A5 (https=
Inventor
エイチ． ラルセン，ロイ
Original Assignee
サイエンコンス エーエス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイエンコンス エーエス filed Critical サイエンコンス エーエス
Publication of JP2025503096A publication Critical patent/JP2025503096A/ja
Publication of JP2025503096A5 publication Critical patent/JP2025503096A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nuclear Medicine (AREA)
JP2024543372A 2022-01-21 2023-01-20 がんの処置および撮像のための複合体 Pending JP2025503096A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22152725.2 2022-01-21
EP22152725 2022-01-21
PCT/EP2023/051355 WO2023139203A1 (en) 2022-01-21 2023-01-20 Complexes for cancer treatment and imaging

Publications (2)

Publication Number Publication Date
JP2025503096A true JP2025503096A (ja) 2025-01-30
JP2025503096A5 JP2025503096A5 (https=) 2026-03-11

Family

ID=79927204

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024543372A Pending JP2025503096A (ja) 2022-01-21 2023-01-20 がんの処置および撮像のための複合体

Country Status (6)

Country Link
US (1) US20250099631A1 (https=)
EP (1) EP4466032A1 (https=)
JP (1) JP2025503096A (https=)
CN (1) CN118891066A (https=)
AU (1) AU2023208408A1 (https=)
WO (1) WO2023139203A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200297877A1 (en) 2017-12-13 2020-09-24 Sciencons AS Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200297877A1 (en) * 2017-12-13 2020-09-24 Sciencons AS Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
EP3856261A1 (en) * 2018-09-28 2021-08-04 Universität Heidelberg Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers

Also Published As

Publication number Publication date
WO2023139203A1 (en) 2023-07-27
CN118891066A (zh) 2024-11-01
AU2023208408A1 (en) 2024-08-01
US20250099631A1 (en) 2025-03-27
EP4466032A1 (en) 2024-11-27

Similar Documents

Publication Publication Date Title
JP7650938B2 (ja) 鉛またはトリウム放射性核種に連結されたｐｓｍａ標的化化合物を含む錯体
US20250057993A1 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of psma-expressing cancers
Yadav et al. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer
Decristoforo et al. 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives
Kao et al. Differentiation of single solid lesions in the lungs by means of single-photon emission tomography with technetium-99m methoxyisobutylisonitrile
Ortiz-Arzate et al. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c (RGDfK)] 2 for breast cancer imaging
Kotzerke et al. Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re-and 99mTc-labeled anti-NCA-95 MAbs
Komal et al. Localization mechanisms of radiopharmaceuticals
Lu et al. Preclinical evaluation of 89Zr/177Lu-labeled amatuximab for theranostic application in pancreatic ductal adenocarcinoma
de Leij et al. Pharmacokinetics and Scintigraphy of Indium 111-DTPA-MOC-31 in Small-Cell Lung Carcinoma
RU2702294C1 (ru) Способ радионуклидной диагностики операбельного рака молочной железы с гиперэкспрессией Her2/neu
JP2025503096A (ja) がんの処置および撮像のための複合体
Prasanphanich et al. The effects of linking substituents on the in vivo behavior of site-directed, peptide-based, diagnostic radiopharmaceuticals
McQuarrie et al. The effects of circulating antigen on the pharmacokinetics and radioimmunoscintigraphic properties of 99m Tc labelled monoclonal antibodies in cancer patients
JP2023552383A (ja) ペプチド受容体放射性核種療法
Yu et al. Evaluation of 111In-DOTA-F56 peptide targeting VEGFR1 for potential non-invasive gastric cancer xenografted tumor mice Micro-SPECT imaging
Hansen et al. Labeling of anti-tumor antibodies and antibody fragments with Tc-99m
Sowa Dumond et al. Concepts and issues for therapeutic radiopharmaceuticals
RU2739107C1 (ru) Способ диагностики рака желудка с гиперэкспрессией Her2/neu
JP4863345B2 (ja) 心筋用放射性画像診断剤又は放射性治療薬
Bruland et al. Targeted radionuclide therapy in bone cancer
Palm et al. Patient-specific alpha-particle dosimetry
Sarwer et al. Localization Mechanisms of
RU2795398C2 (ru) Комплекс, содержащий нацеливающееся на psma соединение, связанное с радионуклидом свинца или тория
Ku et al. Dose predictions for [. sup. 177Lu] Lu-DOTA-panitumumab F (ab'). sub. 2 in NRG mice with HNSCC patient-derived tumour xenografts based on [. sup. 64Cu] Cu-DOTA-panitumumab F (ab'). sub. 2-implications for a PET theranostic strategy.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260123